Biotech Values

[DewDiligence]

>> I wonder if pharma is skeptical about Squalamine's MOA, and long term effects. <<

It doesn’t help that two of the other AMD candidates which are attempting (or have attempted) systemic delivery, OXGN’s CA4P and REGN’s VEGF-Trap, have fared poorly. Perhaps there is some guilt by association in play here.